CellSeed

CellSeed Share Buybacks

The Share Buybacks of CellSeed (7776.T) as of Oct 27, 2026 is 880.77 M JPY. In the previous year, Share Buybacks was 396.89 M JPY — a change of 121.92% (higher).

Share Buybacks

880.77 MJPY

YoY

121.92%

Last updated:

Share Buybacks of CellSeed is 2022 880.77 M JPY. Share Buybacks of CellSeed was 2021 396.89 M JPY. It decreases by 121.92% higher compared to the previous year.

The CellSeed Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2014
853.00 M JPY
Jan 1, 2015
151.00 M JPY
Jan 1, 2016
232.00 M JPY
Jan 1, 2017
1.04 B JPY
Jan 1, 2018
-26,000.00 JPY
Jan 1, 2020
938.68 M JPY
Jan 1, 2021
396.89 M JPY
Jan 1, 2022
880.77 M JPY
The CellSeed Share Buybacks history
YEARShare BuybacksYoY
880.77 MJPY+121.92%
396.89 MJPY-57.72%
938.68 MJPY-3.61 M%
-26,000.00JPY-100.00%
1.04 BJPY+348.28%
232.00 MJPY+53.64%
151.00 MJPY-82.30%
853.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Share Buybacks of CellSeed is 880.77 M JPY in 2022.

Share Buybacks of CellSeed changed from 396.89 M JPY to 880.77 M JPY, representing a 121.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks CellSeed since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's CellSeed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSeed

All Key Metrics — CellSeed